颠覆常规，挑战“不可能”（走近科学大咖⑩）

Core Insights - Pascal Meyer, a pioneer in next-generation sequencing (NGS), revolutionized DNA sequencing technology, which was initially met with skepticism from peers [2][3][6] - Meyer has received prestigious awards, including the 2022 Life Sciences Breakthrough Prize and the 2024 Gairdner International Award, for his contributions to drug development and precision medicine [3] - His company, Alphanosos, is now focusing on the intersection of natural plants and artificial intelligence to address global health challenges [9][12] Company and Industry Overview - Alphanosos is leveraging AI to rapidly identify optimal plant-based compounds for health solutions, significantly reducing research timelines from years to months [9][12] - The company aims to develop personalized treatment plans, aligning with the ancient wisdom of Chinese dietary practices that emphasize individual needs [10][12] - Meyer emphasizes the importance of collaboration between China and Europe in health technology and natural drug research, advocating for a global flow of knowledge and resources [12] Research and Development Focus - The company is targeting complex health issues such as rare genetic disorders and antibiotic resistance, with a vision to create a platform for rapid public health responses [12] - Meyer’s approach combines rigorous scientific inquiry with a commitment to practical solutions, fostering an environment that encourages innovation and risk-taking [11][12] - The integration of AI with life sciences is expected to enhance understanding of personalized medicine and natural health, positioning Alphanosos at the forefront of this evolution [12]